A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT07281937
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 206 participants
- Sponsor
- Verdiva Bio Dev Limited
- Registry
-
NCT07281937
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT07281937. Randomized; triple masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2026-07-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- Acronym
- EVOLVE-2
- Condition
- Obesity
- Condition
- Overweight
- Intervention (Drug)
- VRB-101
- Intervention (Drug)
- Placebo
- Lead sponsor
- Verdiva Bio Dev Limited
Record details
- Record id
cardio:ct-nct07281937- Content hash
b5a241370f480654889d46c37caa54cda2d493cf94db6b361367fc286387f08a